From 365 to 52 Injections
Awiqli (Insulin Icodec) is slated for approval on April 15, 2026. This long-acting basal insulin is designed to be injected just once a week, reducing the burden of care significantly.
Strategic Data Expansion 2026.4
Steady Glycemic Release
Icodec achieves a flat profile via albumin binding. [Image comparing weekly Icodec vs daily glargine glucose levels] LSI keywords like 'ONWARDS trial' and 'basal insulin titration' are now central care plans.
Half-Life Extension
Weekly Elimination Constant
$$t_{1/2} \approx 196 ext{ hours}$$
Strategic Advice: If you are on daily basal insulin, ask about 'The Weekly Switch' in late 2026.